A health care worker fills up a syringe with a dose of Moderna's COVID-19 vaccine for a booster shot at the vaccination reference center at the Epidemiology, Biostatistics and Prevention Institute in Zurich, Switzerland November 17, 2021. REUTERS/ Arnd Wiegmann/ File Photo
Cancer patients who received mRNA-based COVID vaccines within 100 days of starting treatment with widely used immunotherapies were twice as likely to be alive three years after beginning treatment, researchers reported.
Among 180 such patients with advanced non-small cell lung cancer who received an mRNA-based COVID vaccine from Moderna or Pfizer/BioNTech, the median survival, or the point at which half the patients had died, was 37.33 months.
Continue Reading on GMA News
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.